Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Electrotransport delivery device having improved safety and reduced abuse potential|
|Abstract:||An electrotransport device (20) for delivering one or more therapeutic agents through the skin includes electrodes (30,32) for contacting the skin (34), at least one electrode containing the agent, a power source (22) for generating electrical current (I.sub.L) for delivering the agent, a current generating and controlling means (24), and a disabling means (26) for permanently and irreversibly disabling the current. The disabling means (26) may include a timer means (66), a counter means (82), or a body parameter sensor (134) and limit comparator (132) to effect permanent disabling. The disabling means may be a permanent transition to a disabled logic state, a permanent discharge of a power supply source (22), or a permanent diversion of electrotransport current from the electrodes (30,32), or a combination of the above. The permanent disabling means may include a circuit connection means (304,308,326,328) having a frangible conducting member (332) which permanently fractures and causes an irreversible open circuit in the connection to the electrodes (334,342) upon removing a disposable/single use electrode assembly (300) from a reusable portion of an electrotransport device.|
|Inventor(s):||McNichols; Larry A. (Coon Rapids, MN), Badzinski; John D. (Coon Rapids, MN), Reining; William N. (Cross Plains, WI), Lattin; Gary A. (Forest Lake, MN), Haak; Ronald P (Menlo Park, CA), Phipps; Joseph B. (Plymouth, MN)|
|Assignee:||ALZA Corporation (Mountain View, CA)|
Patent Claim Types:|
see list of patent claims
|Delivery; Device; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.